<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268592</url>
  </required_header>
  <id_info>
    <org_study_id>10-204A</org_study_id>
    <nct_id>NCT01268592</nct_id>
  </id_info>
  <brief_title>Fertility Preservation in Female Cancer Patients</brief_title>
  <official_title>Vitrification of Oocytes From Female Cancer Patients to Preserve Their Fertility Potential</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to preserve the fertility potential in females diagnosed with
      cancer by vitrifying (rapidly freezing) their oocytes (eggs) before undergoing treatment for
      their cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study technique has been declared part of standard care
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>successful pregnancy</measure>
    <time_frame>nine months after transfer of embryo(s)</time_frame>
    <description>the primary objective of this study is the establishment of a successful pregnancy, following a disease-free interval after treatment for her cancer; this interval will be patient-dependent and will undoubtedly vary between participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>impact of stimulation on cancer recurrence</measure>
    <time_frame>5 years after treatment</time_frame>
    <description>patients will be followed for five years following cancer treatment to assess the risks associated with ovarian stimulation and the recurrence of cancer.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Fertility</condition>
  <arm_group>
    <arm_group_label>positive cancer diagnosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>female patients diagnosed with cancer who wish to preserve their fertility by vitrifying their oocytes</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>oocyte vitrification</intervention_name>
    <description>freezing of the patient's retrieved oocytes via vitrification (rapid freezing)</description>
    <arm_group_label>positive cancer diagnosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be 14-42 year old females with a cancer diagnosis.

          -  Clearance letter from treating oncologist.

          -  Approval by program oncologist or her designee.

          -  Informed consent has to be signed after consultation with the program physician.
             Minors require consent of a parent or a legal guardian and assent from the
             participant.

          -  Life expectancy (predicted by their malignancy) of 5 or more years.

          -  Cancer diagnosis should have an expected cure rate of 50% or more, based upon
             clinico-pathologic features.

        Exclusion Criteria:

          -  Patients whose oncologist and the program oncologist concur that immediate oncologic
             care should be rendered, not allowing sufficient time for a course of gonadotropin
             therapy and egg retrieval.

          -  FSH level &gt;20 MIU/ml, indicating abnormal ovarian function.

          -  Patients with stage IV cancers (*age appropriate women with stage IV advanced
             Hodgkin's Lymphoma will be considered, as there is a significant long term survival
             rate with this advanced disease).

          -  Patients with incurable cancer diagnoses.

          -  Patients who are unable or unwilling to sign the informed consent.

          -  Women cannot have an embryo transfer beyond age 50.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avner Hershlag, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Human Reproduction</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Human Reproduction</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ajala T, Rafi J, Larsen-Disney P, Howell R. Fertility preservation for cancer patients: a review. Obstet Gynecol Int. 2010;2010:160386. doi: 10.1155/2010/160386. Epub 2010 Mar 31.</citation>
    <PMID>20379357</PMID>
  </reference>
  <reference>
    <citation>Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008 Jun 1;26(16):2630-5. doi: 10.1200/JCO.2007.14.8700.</citation>
    <PMID>18509175</PMID>
  </reference>
  <reference>
    <citation>Azim AA, Costantini-Ferrando M, Lostritto K, Oktay K. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab. 2007 Jun;92(6):2197-200. Epub 2007 Mar 13.</citation>
    <PMID>17356042</PMID>
  </reference>
  <reference>
    <citation>Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med Pediatr Oncol. 1999 Jul;33(1):29-33. Review.</citation>
    <PMID>10401494</PMID>
  </reference>
  <reference>
    <citation>Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril. 2005 Jun;83(6):1622-8.</citation>
    <PMID>15950628</PMID>
  </reference>
  <reference>
    <citation>Ganz PA. Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. Am J Med. 2005 Dec 19;118 Suppl 12B:136-41.</citation>
    <PMID>16414339</PMID>
  </reference>
  <reference>
    <citation>Gook DA, Edgar DH. Human oocyte cryopreservation. Hum Reprod Update. 2007 Nov-Dec;13(6):591-605. Epub 2007 Sep 10. Review.</citation>
    <PMID>17846105</PMID>
  </reference>
  <reference>
    <citation>Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril. 2010 Feb;93(2):391-6. doi: 10.1016/j.fertnstert.2009.02.067. Epub 2009 May 12.</citation>
    <PMID>19439285</PMID>
  </reference>
  <reference>
    <citation>Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 2009 Feb 26;360(9):902-11. doi: 10.1056/NEJMra0801454. Review.</citation>
    <PMID>19246362</PMID>
  </reference>
  <reference>
    <citation>Knopman JM, Noyes N, Talebian S, Krey LC, Grifo JA, Licciardi F. Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril. 2009 Apr;91(4 Suppl):1476-8. doi: 10.1016/j.fertnstert.2008.07.1727. Epub 2008 Sep 18.</citation>
    <PMID>18804204</PMID>
  </reference>
  <reference>
    <citation>Quintero RB, Helmer A, Huang JQ, Westphal LM. Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril. 2010 Feb;93(3):865-8. doi: 10.1016/j.fertnstert.2008.10.007. Epub 2008 Nov 14.</citation>
    <PMID>19013563</PMID>
  </reference>
  <reference>
    <citation>Kumayama M and Kato O. All-round vitrification method for human oocytes and embryos. J Asst Reprod Gen 17:447, 2000.</citation>
  </reference>
  <reference>
    <citation>Nagy ZP, Chang CC, Bernal DP, Shapiro D, Mitchell-Leef D and Kort HI. Comparison of laboratory and clinical outcomes between fresh and vitrified sibling oocytes obtained from 30-39 year old IVF patients. Fertil Steril 92, Supp3:S67, 2009.</citation>
  </reference>
  <reference>
    <citation>Nagy ZP, Chang CC, Shapiro DB, Bernal DP, Elsner CW, Mitchell-Leef D, Toledo AA, Kort HI. Clinical evaluation of the efficiency of an oocyte donation program using egg cryo-banking. Fertil Steril. 2009 Aug;92(2):520-6. doi: 10.1016/j.fertnstert.2008.06.005. Epub 2008 Aug 9.</citation>
    <PMID>18692830</PMID>
  </reference>
  <reference>
    <citation>Noyes N, Boldt J, Nagy ZP. Oocyte cryopreservation: is it time to remove its experimental label? J Assist Reprod Genet. 2010 Feb;27(2-3):69-74. doi: 10.1007/s10815-009-9382-y. Epub 2010 Feb 6. Review. Erratum in: J Assist Reprod Genet. 2010 May;27(5):259.</citation>
    <PMID>20140641</PMID>
  </reference>
  <reference>
    <citation>Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, Bang H. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006 Oct;91(10):3885-90. Epub 2006 Aug 1.</citation>
    <PMID>16882752</PMID>
  </reference>
  <reference>
    <citation>Porcu E, Bazzocchi A, Notarangelo L, Paradisi R, Landolfo C, Venturoli S. Human oocyte cryopreservation in infertility and oncology. Curr Opin Endocrinol Diabetes Obes. 2008 Dec;15(6):529-35. doi: 10.1097/MED.0b013e3283199129. Review.</citation>
    <PMID>18971682</PMID>
  </reference>
  <reference>
    <citation>Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013 Jan;99(1):37-43. doi: 10.1016/j.fertnstert.2012.09.028. Epub 2012 Oct 22.</citation>
    <PMID>23083924</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2010</study_first_posted>
  <last_update_submitted>April 22, 2013</last_update_submitted>
  <last_update_submitted_qc>April 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fertility preservation</keyword>
  <keyword>oocyte cryopreservation</keyword>
  <keyword>vitrification</keyword>
  <keyword>egg freezing</keyword>
  <keyword>fertility preservation in female cancer patients</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

